IP Library › Patent Application 13364810
Patent Application
App. No. 13/364,810

ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/364,810
Abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.

Claims (8)

1 . An isolated, cross-reactive monoclonal antibody that binds to both IL-17A (SEQ JD NO:2) and IL-17F (SEQ ID NO:4), wherein said antibody binds to a discontinuous IL-17F epitope comprising amino acid residues 105-109 and 147-152 of SEQ ID NO:4 and a discontinuous IL-17A epitope comprising amino acid residues 107-111 and 149-154 of SEQ ID NO:2; and wherein said antibody reduces the pro-inflammatory activity of both IL-17A and IL-17E.

2 . The antibody of claim 1 , wherein said antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a human antibody.

3 . The antibody of claim 1 , wherein said antibody is a single chain antibody.

4 . The antibody of claim 1 , wherein said antibody is an antibody fragment.

5 . The antibody of claim 4 , wherein the antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv antibody fragments.

6 . A composition comprising:

the antibody according to claim 1 ; and

a pharmaceutically acceptable vehicle, carrier, or excipient.